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a b s t r a c t
Chronic myeloid leukemia (CML) is a malignant disease of progenitor myeloid cells cau-
sed by chromosomal translocation that results in the forming of diminutive Philadephia
chromosome that harbors BCR/ABL fusion oncogene. The product of this oncogene,
a tyrosine kinase, alters several important regulatory pathways related to cell growth
and differentiation thus leading to cancer transformation. Major form of CML therapy is
based on tyrosine kinase inhibitors, first of all imatinib (IM). Some patients develop resis-
tance to IM in the course of treatment. In the process of leukemogenesis the activity of
miRNAs – one of groups of RNAs involved in RNA interference (RNAi) – is altered. Signa-
tures of altered miRNAs activity may serve as a prognostic factor in the development
and therapy of several diseases. Moreover, other group of RNAs involved in RNAi – siRNA
– might be valuable addition to array of specific therapeutics targeted the BCR/ABL
kinase.
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Chronic myeloid leukemia (CML) is probably one of the most
extensively studied human malignancies. It is associated
with a consistent chromosomal abnormality – the Philadel-
phia (Ph) chromosome [1]. The Ph chromosome results from
a reciprocal translocation t(9;22)(q34;q11) which involves the* Corresponding author at: Katedra Genetyki Molekularnej, Wydział B
Poland.
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http://dx.doi.org/10.1016/j.achaem.2013.07.001ABL proto-oncogene on chromosome 9 and BCR (for break-
point cluster region) on chromosome 22 [2]. This transloca-
tion creates the BCR/ABL fusion gene which encodes the
BCR/ABL protein, a tyrosine kinase protein that is believed
to be the principal cause of the CML pathogenesis [1, 3].
Molecular signaling in CML affected by BCR/ABL is highly
complex and activates multiple signal transduction path-
ways (see [1, 2] for more details). The activity of BCR/ABLiologii i Ochrony Środowiska, ul. Pomorska 141/143, 90-263 Łódź,
ematologii i Transfuzjologii. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Fig. 1 – Biogenesis of miRNA. miRNAs are derived from
endogenous precursors processed by the microprocessor
complex, exported to cytoplasm, processed by DICER and
loaded onto AGO protein forming mature RISC complexes
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ence of leukemia cells to the bone marrow, and reduced
apoptosis what results in the malignant expansion of
pluripotent stem cells in bone marrow [3]. CML is subdivided
into three phases: chronic phase (CP), which is the initial
phase and disease, is usually diagnosed at this stage.
Subsequently, it advances to an accelerated phase (AP). The
last CML phase is called blast crisis (BC) [1]. Since CML is
caused by BCR/ABL it was possible to design an effective
targeted molecular therapy which selectively inhibits the
aberrant BCR/ABL protein [4]. Imatinib mesylate (imatinib,
IM, STI-571, Glivec®, Novartis Pharma) is a BCR/ABL tyrosine
kinase inhibitor that is used for the treatment of CML. IM
blocks the ATP-binding site and stabilizes the inactive form
of BCR/ABL thus blocking downstream signal transduction
pathways affected by this protein [4].
RNA interference (RNAi) is a process, in which small
non-coding RNAs (ncRNAs) incorporated into multi-protein
RNA-induced silencing complex (RISC) repress gene activity
in a sequence-specific manner at transcriptional, post-tran-
scriptional or translational level [5, 6]. The process of RNA-
mediated gene silencing has an essential role in cell devel-
opment, differentiation, proliferation, apoptosis, maintain-
ing of chromatin structure, virus resistance and oncogenesis
[7]. There are three types of small ncRNAs including micro
RNA (miRNA), small interfering RNA (siRNA) and Piwi-
interacting RNA (piRNA) [8]. In our review we will focus on
siRNA and miRNAs as best understood groups of small
ncRNAs, and their role in processes of leukemogenesis and
interaction with signaling and regulatory pathways, in
which BCR/ABL kinase is active.
Biogenesis of miRNA and siRNA
Micro RNAs are small, approximately 22 nt long, RNAs that
are derived from endogenous hairpin-shaped transcripts
through the action of the Drosha and Dicer proteins, and
subsequently bound by Ago-family proteins forming mature
RISC complexes [9] (Fig. 1). Some of miRNA genes are
located in introns of pre-mRNAs [10]. Other miRNA genes
are clustered in the genome with an arrangement and
expression pattern indicating polycistronic primary tran-
scripts [11]. The primary transcripts of miRNA (pri-miRNAs)
are usually generated by RNA polymerase II [12]. They are
processed in the nucleus by Microprocessor complex, which
contains Drosha and DGCR8, also known as Pasha, proteins
[9, 13]. The pre-miRNAs are transported to the cytoplasm,
where they undergo further processing by the Dicer protein,
which cleaves dsRNA and releases a 22-nucleotide mature
double-stranded miRNAs. One strand of the miRNA duplex
is subsequently loaded onto the Ago protein, and then
incorporated into fully functional RISC complex, while the
other one, called passenger RNA, being degraded [9, 14, 15].
Small interfering RNAs are slightly shorter than miRNAs
and are around 21 nt long. Originally siRNAs were believed
to be exclusively derived from the exogenous RNA [6].
However, endogenous siRNA (endo-siRNA) were recently
discovered in Drosophila melanogaster, mouse oocytes and
some stem cells (reviewed in [9]). Similarly to miRNAs theyform RISC complexes with Ago-family proteins [16], but they
differ in their biogenesis. Their origin stems from long
double-stranded RNAs are processed with Dicer but without
Drosha activity (Fig. 2) [9]. Exogenous siRNAs may come
from processed viral RNA [17], while endo-siRNA originates
from precursors created through transcription of sense-
antisense pairs of transposons, or from long, self-paired,
double-stranded fragment of mRNAs [18].
RNA interference mediated by mi- and siRNAs
The core activity of mi- and siRNAs is similar: they allow for
specific modulation of gene expression through guiding the
activity of RISC complexes. The complex contains Ago,
which is believed to be a core element of it with its ability
to bind to single-stranded RNA (ssRNA) and dsRNA [19, 20].
After recognition of complementarity between targeted
mRNA and mi- or siRNA template, RNase activity of RISC is
induced, leading to degradation of mRNA [21].
The miRNAs can direct the RISC to downregulate gene
expression by mRNA cleavage or translational repression.
The pathway of silencing is determined by the kind of the
target: the RISC will specify cleavage of the target mRNA if
the mRNA has sufficient complementarity to the mRNA or it
will repress productive translation if the mRNA does not
Fig. 2 – Biogenesis of siRNA. siRNAs can be derived both from endogenous precursors encoded in the genome as well as from
exogenous double-stranded RNAs. Processing of endogenous precursors occurs without Drosha activity. After being
exported into cytoplasm double stranded miRNA precursors are processed by DICER complex and loaded onto AGO protein
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Recently, it was also shown that miRNAs could induce
transcriptional silencing in human cells, directing Ago1,
Polycomb group (PcG) and histone methyltransferase enhan-
cer of zeste homolog1 (EZH2) recruitment to specific DNA
sequences, altering histone methylation status [22]. Over the
several past years it was shown that miRNAs are able to
repress the expression of important cancer-related genes
and expression of miRNA genes contribute to the pathogen-
esis of human malignances [23].
Small interfering RNAs can repress gene activity through
transcriptional gene silencing in human cells [5]. This
mechanism needs an mRNA transcribed with 50 extended
untranslated region overlapping with gene promoter, and
probably involves some modification in methylation status
[24, 25]. For example, after exposure to the siRNA, the
targeted promoter exhibits higher levels of the silencing
histone methyl marks H3 lysine-9 di-methylation (H3K9me2)
and histone H3 lysine-27 tri-methylation (H3K27me3) [26].
However, the role that DNA methylation plays in thistranscriptional silencing remains uncertain, as siRNA
mediated transcriptional gene silencing was observed in the
absence of increased DNA methylation at the targeted
promoter, but these observations were not confirmed in other
studies [27, 28]. In addition, the question how exactly siRNAs
recognize and modulate transcriptional gene silencing
through histone methylation remains unanswered [24]. Pre-
sumably, transcriptional gene silencing involves DNA methyl-
transferase 3a (DNMT3a), Ago1 as well as Ago2, HDAC-1 and
EZH2 and/or G9a [24, 26, 29–31]. Despite the role of siRNA in
transcriptional gene silencing, they were also reported to act
in gene activation in human cells [29, 32].
Interaction between miRNAs and BCR/ABL
There is growing evidence that miRNAs may play an
important role in BCR/ABL-dependent malignancies (see
Table I and Fig. 3). For example, miR-203 controls the
expression of the ABL1 gene as well as the fusion oncogene
Table I – Micro RNAs (miRNAs) expressed in cells harboring BCR/ABL kinase
miRNA Feature Reference
miR-7 Down regulated in IM-responding CML patients [44]
miR-10a Down regulation in CML, not BCR/ABL-dependent. Target of this miRNA
is a growth factor
[36]
polycistronic miR17-92 cluster Down regulated by IM action and siRNA targeted at BCR/ABL. [37]
miR-23a/26a/29a/29c Down regulated in IM-responding CML patients [44]
miR-30a Inhibited by IM, acts as inhibitor of autophagy [45]
miR-30b/30c Down regulated in IM-responding CML patients [44]
miR-31 BCR/ABL-dependent down regulation in CML cells [39]
miR-96 BCR/ABL-dependent down regulation in CML cells [36]
miR-100/126# Down regulated in IM-responding CML patients [44]
miR-130a/b Down regulated after BCR/ABL knockdown, negatively regulates anti-
growth factor CCN3
[40]
miR-134/141 Down regulated in IM-responding CML patients [44]
miR-138 Decreases activity of BCR/ABL, sensitizes to IM action [38]
miR-150 BCR/ABL-dependent down regulation in CML cells [36, 41, 42]
miR-151 BCR/ABL-dependent down regulation in CML cells [36]
miR-155 BCR/ABL-dependent down regulation in CML cells [39]
miR-183/191/196b/199a Down regulated in IM-responding CML patients [44]
miR-203 Lost through deletion in some hematopoetic malignancies. This miRNA
down regulates ABL1, including infusion with BCR.
[33]
miR-224/326/422b/520a Down regulated in IM-responding CML patients [44]
miR-564 BCR/ABL-dependent down regulation in CML cells [39]
a c t a h a e m a t o l o g i c a p o l o n i c a 4 4 ( 2 0 1 3 ) 3 6 3 – 3 6 9366BCR/ABL. It was demonstrated that increased levels of miR-
203 expression resulted in a decreased expression of BCR/
ABL [33]. Moreover, an inhibition of BCR/ABL expression with
miR-203 sensitized BCR/ABL-positive cells to IM action [34].
Another study suggests the presence of a reciprocal regula-
tory loop between BCR/ABL and miR-451 inducing the inhibi-
tion of miR-451 by theBCR/ABL activity. Because miR-451 is
BCR/ABL negative regulator, this results in the increased
expression of BCR/ABL. Moreover, this process may lead to
synergy in the activity of miRNA and BCR/ABL tyrosine
inhibitor IM [35]. Other interactions may include synergy in
oncogenic activity between some miRNAs and BCR/ABL
kinase itself. One such case is miR-125b that was found
over-expressed up to 90 times in acute myeloid leukemia
cells with chromosomal translocation t(2;11)(p21;q23), and
could accelerate leukemia development even when co-
expressed with BCR/ABL [36].
Recent findings show that specific miRNAs may play
a fundamental role in the activation of oncogenic signal
transduction pathways in CML cells. A decreased expression
of miR-326 was reported to lead to unrestricted activity of
Smo transducer, a key player in the Hedgehog pathway, in
CML cells [37]. Similarly, miR-138 acts in mini circuitry with
BCR/ABL and GATA1, an important factor in regulation of
erythroid and megakaryocytic development. Overexpression
of miR-138 decreases BCR/ABL activity. Conversely, IM treat-
ment increases miR-138 activity, which in turn activates
GATA1 [38].
As shown above miRNAs can directly modulate the
expression of BCR/ABL. However, the tyrosine kinase activ-
ity of BCR/ABL was also shown to contribute to the
expression of distinct miRNAs. Although changes in activ-
ity of many miRNAs are observed in CML cells, not all are
BCR/ABL-dependent. It was shown that hsa-miR-10a, hsa-
miR-150, and hsa-miR-151 were down-regulated, whereas
hsa-miR-96 was up-regulated in CML CD34+ cells. Amongthese miRNAs, only activity of hsa-miR-150 and hsa-miR-
151 was related to BCR/ABL kinase function, which was
assessed by inactivation of BCR/ABL by IM [39]. It was
reported that miR-17-92 cluster was expressed in a BCR/
ABL-dependent manner, and expression of pri-miR-17-92
was also mediated by myelocytomatosis oncogene (c-MYC).
In addition, miR-17-92 miRNAs were overexpressed in CML
cells in CP, but not in BC [40]. Another study showed that
miR-31, miR-155, miR-564 and, miR-328 despite possessing
distinct targets, were downregulated and this effect was
dependent on BCR/ABL tyrosine kinase activity [41, 42]. More-
over, the downregulation of miR-328 was also dependent on
BCR/ABL in dose-dependent manner [41]. BCR/ABL was
reported to upregulate some miRNAs and in consequence
inhibit negative growth regulators and promoting cell growth.
As an example of these may be miR-130a and -130b. Expres-
sion of miR-130a and miR-130b was observed to be BCR/ABL-
dependent, but the exact mechanism by which BCR/ABL
affects the expression of these miRNAs remains unknown.
However, apparently after stimulation of the activity of these
miRNAs by BCR/ABL inhibition of CCN3 negative growth
regulator occurs promoting cell proliferation. [43].
Micro RNAs and therapy of BCR/ABL dependent
leukemias
The use of IM revolutionized treatment of CML [4]. Despite the
clinical success obtained with IM, resistance to this drug is an
emerging problem [3]. Since abnormal expression of miRNAs
was described in leukemias, miRNAs may modulate response
to IM treatment in CML patients. It was reported that
lentivirus-mediated over-expression of polycistronic miRNAs
of miR-17-92 cluster enhanced response to IM [40]. It was
also shown that miR-150 and miR-146a were upregulated,
while miR-142-3p and miR-199b-5p were downregulated after
Fig. 3 – Interaction between BCR/ABL and miRNAs. miRNAs
may inhibit activity of BCR/ABL ormay be inhibited by this
kinase. This may lead to synergistic interactions between
some miRNAs and kinase inhibitors such as imatinib (IM).
Moreover, as it is in the case of miR-451 negative
interactions between BCR/ABL and miRNAs may form
reciprocal interactions resulting in mutual downregulation.
BCR/ABL may also act with synergy on other miRNAs, as in
the case of promoting cell growth with miR-130, a negative
regulator of CCN3, which functions as a cell growth
inhibitor
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that aberrant expression level of these miRNAs was returning
toward normal levels as seen in healthy donors, suggesting
that miRNAs, by regulating distinct genes, may be involved in
BCR/ABL-driven leukemogenesis [46]. Another study, which
was aimed at identifying miRNAs and their related targets
associated with CML pathogenesis, revealed that miR-150,
miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-
181a, miR-221 and miR-222 were deregulated in CML [47].
However, stating if they function in dependence or indepen-
dence of BCR/ABL needs further investigation [47]. Micro RNAs
may also play a role in the development of IM-resistance. It
was shown that IM inhibits expression of miR-30a, which
functions as inhibitor of autophagy through downregulation
of Beclin 1 and ATG5 expression. Autophagy, in turn, is one of
ways of avoiding cell death induced by IM treatment. Thus
this miRNA may serve as a basis for mechanism of IM-
resistance. It was shown that decreased levels of miR-30a
correlated with increased levels of ABL1 and BCR/ABL expres-
sion [48].Since growing numbers of patients are suffering from
resistance to IM it is necessary to find markers which will
enable identification of patients who may develop such
resistance. One kind of such markers might be specific
signatures of altered miRNA activity. It was revealed that
a group of 19 miRNAs may function as predictors for IM
resistance in newly diagnosed CML patients [44]. Among
them 18 were downregulated and only one was upregulated
[44]. Another study showed that miR-451 was downregu-
lated in IM-resistant patient as compared to IM-responding
patients suggesting that miR-451 expression levels are
correlated with response to IM therapy [49]. Nevertheless,
further studies are required to confirm and validate the role
of miRNAs as novel markers in predicting IM resistance.
In recent years a new area of potential drug development
emerged, that aims synthetic siRNAs targeted at specific
oncogenes as a means of suppressing their activity. Several
attempts were performed for evaluation of validity of that
method for treatment of BCR/ABL-induced leukemias. It was
demonstrated that delivery of double-stranded RNA targeted
at BCR/ABL oncogene resulted in RNAi that caused BCR/ABL
inhibition and death of leukemic cells [50]. Activity of RNAi-
based inhibitors appears to be even more specific than
classical tyrosine inhibitors. snRNA designed for targeting
specific variants of BCR/ABL – formed by b3a2 breakpoint –
induced cell death only in cells carrying this specific variant
of that gene [51]. Successes in inducing cell death in
leukemic cells with siRNA targeted at BCR/ABL led to
evaluation of combined treatments with classical tyrosine
inhibitors and siRNAs. Delivery of IM to K-562 cells carrying
BCR/ABL together with siRNA targeted at this oncogene
resulted in 3-fold decrease in IM EC50 [52]. Synergism was
also observed between action of siRNAs targeted at BCR/ABL
and other oncogenes [53]. Synthetic siRNAs were also used
for overcoming IM resistance in patient with CML recurring
after IM therapy. These results suggest that siRNAs may be
feasible in CML therapy [54]. Similar results were obtained
in vitro for leukemic cells derived from patient with relapsed
acute myeloid leukemia, who exhibited Ph+ chromosome de
novo during clinical treatment. Delivery of siRNA resulted in
cell-death induction in cells resistant to IM [55]. Moreover, it
was demonstrated that siRNAs could overcome IM-resis-
tance based both on BCR/ABL overexpression and its point
mutations [56].
Future perspectives
Current findings indicate that many intertwined pathways
involving BCR/ABL kinase activity and miRNA epigenetic
modulation of gene expression are present in leukemic cells.
Those mutual influences may be positive or negative in
nature. Because recent advances in understanding the role of
small non-coding RNAs provide a plenty of newly identified
miRNAs and siRNAs this area of research may create a new
opportunities for studying of mechanisms of cancer transfor-
mation. Moreover, this may lead to development of new
therapies, or to reinforcement of treatment potential of
currently used drugs. However, there are some obstacles. The
sole task of annotating snRNAs involved in modulating
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annotated snRNAs without any real functional meaning are
present in databases [9]. This may make finding of new
interactions between BCR/ABL and snRNAs complicated.
Nevertheless, there is no doubt that epigenetics in
general, and snRNAs specifically, will be one of major area
of interests in coming years. In case of many leukemias,
especially CML, genetic components of cancer transforma-
tion are relatively well understood. Yet still many differ-
ences in disease development as well as therapy response
are observed between different patients. It is apparent that
mechanisms of epigenetic nature are one of major factor
responsible for that differences. Thus unraveling the com-
plex web of mutual interactions between genetic and
epigenetic factors involved in determining the way in which
normal cells undergo cancer transformation is essential for
future development of diagnosing and treating of leukemias.
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